|
[1]
|
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. http://d.old.wanfangdata.com.cn/Periodical/zhzl201210017
|
|
[2]
|
Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma[J]. Semin Radiat Oncol, 2018, 28(4):277-287. doi: 10.1016-S0360-3016(03)00434-6/
|
|
[3]
|
Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients[J]. Acta Oncol, 1995, 34(6):861-870. doi: 10.3109-02841869509127197/
|
|
[4]
|
Benson AR, D'Angelica MI, Abbott DE, et al. NCCN guidelines insights:hepatobiliary cancers, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5):563-573. http://d.old.wanfangdata.com.cn/Periodical/lcgdbzz201805009
|
|
[5]
|
Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization[J]. Cancer, 2012, 118(21):5424-5431. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1002/cncr.27533
|
|
[6]
|
Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31(13):1631-1639. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b3977d927b084fe210bba9054456cb95
|
|
[7]
|
Lee DS, Woo JY, Kim JW, et al. Re-irradiation of hepatocellular carcinoma:clinical applicability of deformable image registration[J]. Yonsei Med J, 2016, 57(1):41-49. http://cn.bing.com/academic/profile?id=c7f9d4746ecaec04dfc922347ada0df5&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[8]
|
Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy:the report of AAPM Task Group 101[J]. Med Phys, 2010, 37(8):4078-4101. http://cn.bing.com/academic/profile?id=248f2e38f4dd7c854a7827f28629481a&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[9]
|
Korean Liver Cancer Study Group (KLCSG). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma[J]. Gut Liver, 2015, 9(3):267-317. http://cn.bing.com/academic/profile?id=2b9b6c376b84fbdd4e993b6e64e3436d&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[10]
|
Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies[J]. Int J Radiat Oncol Biol Phys, 2010, 78(2):486-493. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=53c0a1175290a4402c160a0e3aa2dbb1
|
|
[11]
|
Cardenes HR, Price TR, Pekins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma[J]. Clin Transl Oncol, 2010, 12(3):218-225. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4c716dc2649f3f42f15db9e33a2d1629
|
|
[12]
|
Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):447-453. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_431321ff0096f7e82ca6b38b24aa29e1
|
|
[13]
|
Su TS, Liang P, Lu HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients[J]. J Surg Oncol, 2016, 113(2):181-187. http://d.old.wanfangdata.com.cn/Periodical/xhwk201807018
|
|
[14]
|
Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2):355-361. http://cn.bing.com/academic/profile?id=7c42c8fcb899c68370016c12c0891b57&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[15]
|
Kimura T, Aikata H, DoiY, et al. Comparison of stereotactic body radiation therapy combined with or without transcatheter arterial chemoembolization for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies[J]. Technol Cancer Res Treat, 2018, 17:p. 1533033818783450. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0224489361/
|
|
[16]
|
Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:a retrospective outcome analysis in 185 patients[J]. Acta Oncol, 2014, 53(3):399-404. http://cn.bing.com/academic/profile?id=11a71ca82d04158f1353083d035d528c&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[17]
|
Kuo HT, Que J, Lin LC, et al. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma[J]. Medicine (Baltimore), 2017, 96(50):e9249. http://cn.bing.com/academic/profile?id=08c88e2c9cced3a71b1d5ca5cad02f34&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[18]
|
Su TS, Lu HZ, Cheng T, et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5cm[J]. BMC Cancer, 2016, 16(1):834. https://www.ncbi.nlm.nih.gov/pubmed/27809890
|
|
[19]
|
O'Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl, 2012, 18(8):949-954. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=faec621bea2173b217c368dacb1b0125
|
|
[20]
|
Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017, 67(1):92-99. http://d.old.wanfangdata.com.cn/Periodical/zgyxzb201501028
|
|
[21]
|
Sharabi AB, Nirschl CJ, Kochei CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J]. Cancer Immunol Res, 2015. 3(4):345-355. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7a258595e47d46e541888c42e915397c
|
|
[22]
|
Chiang CL, Chan ACY, Chiu KWH, et al. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma:a potential synergistic treatment strategy[J]. Front Oncol, 2019, 9:1157. http://cn.bing.com/academic/profile?id=ef44719e1d2ca09a1b0371e244caa04c&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[23]
|
Dawson LA, Ten HR. Partial volume tolerance of the liver to radiation[J]. Semin Radiat Oncol, 2005, 15(4):279-283. http://cn.bing.com/academic/profile?id=78aadeeec4d65cf7d23d3d683baa4b91&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[24]
|
Wang PM, Chung NN, Hsu WC, et al. Stereotactic body radiation therapy in hepatocellular carcinoma:Optimal treatment strategies based on liver segmentation and functional hepatic reserve[J]. Rep Pract Oncol Radiother, 2015, 20(6):417-424. http://cn.bing.com/academic/profile?id=a92e4af2bf48aa441a55139c4ef99f17&encoded=0&v=paper_preview&mkt=zh-cn
|
|
[25]
|
Bae SH, Kim MS, Jang WI, et al. Low hepatic toxicity in primary and metastatic liver cancers after stereotactic ablative radiotherapy using 3 fractions[J]. J Korean Med Sci, 2015, 30(8):1055-1061. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=6f382f065deee9a57a7fb413f66f6c63
|
|
[26]
|
Liu X, Song Y, Liang P, et al. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients[J]. Onco Targets Ther, 2017, 10:5289-5295. http://cn.bing.com/academic/profile?id=a56c833ad9b46367f885b316dba5c3d1&encoded=0&v=paper_preview&mkt=zh-cn
|
点击查看大图
下载:
